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Abstract  
INTRODUCTION: The most common method to compare olanzapine and risperidone is by calculating the score 
of positive and negative syndromes scale (PANSS). However, there were some conflicting results mentioned from 
previous studies.  
AIM: This study aimed to compare the treatment of olanzapine and risperidone using PANSS, limited to only male 
patients receiving inpatient treatment to obtain more significant results. 
METHODS: The subjects of this study were male schizophrenic patients in the acute phase of treatment (N = 68) 
who were hospitalised at the Mental Hospital Prof. Dr M. Ildrem, Indonesia. These participants were divided into 
two groups and treated with different atypical antipsychotics (olanzapine, 20 mg/day [n = 34]; risperidone, 6 
mg/day [n = 34]). The scores of PANSS from both groups were collected from pre-test and post-test after 6 -week 
treatment. 
RESULTS: The improvement of the schizophrenia symptoms measured by PANSS after 6 weeks showed 
significant differences in the scores of PANSS between the male patient groups treated with olanzapine and 
risperidone (p-value < 0.001). 
CONCLUSION: The group of olanzapine shows a higher improvement of the scores of PANSS than that the 
group of risperidone. 
 
 
 
 
 
Introduction 
 
Schizophrenia is a psychotic disorder 
characterised by a disorder of mind, mood, and 
behaviour. Schizophrenia accounts for around 1% of 
the population. This disorder usually starts before the 
age of 25, survives throughout life, and may affect 
people from all social classes. Schizophrenia consists 
of positive symptoms, negative symptoms, cognitive 
symptoms, aggressive symptoms, and affective 
symptoms. The positive symptoms include delusions, 
hallucinations, disorganised speech or behaviour, 
catatonic behaviour, and agitation. The negative 
symptoms include blunted or flat affect, emotional 
withdrawal, poor rapport, indifference, withdrawal from 
social life, abstract-thought disorder, alogia, avolition, 
anhedonia, and concentration disorder [1]. 
Among atypical antipsychotics, risperidone 
and olanzapine have been shown to reduce both the 
positive and the negative symptoms significantly of 
schizophrenia [2], and are also more effective than 
conventional antipsychotic drugs [3]. Risperidone and 
olanzapine exploit multiple actions on serotonin and 
dopamine which resulted in improved adherence by 
minimising the side effects of extrapyramidal [4] [5]. 
One way of measuring the positive symptoms, 
the negative symptoms, and the general symptoms in 
schizophrenic patients is by using Positive and 
Negative Syndrome Scale (PANSS). The 
measurement of the scores of PANSS has been 
proven to be sensitive and specific about the use of 
pharmacology from the assessment of the positive 
symptoms and the negative symptoms in 
schizophrenic patients [6]. Several studies have been 
conducted to compare the effectiveness of olanzapine 
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and risperidone using the scores of PANSS. Conley et 
al. (2001) found that olanzapine leads to better 
improvement in both positive and negative symptoms, 
better overall response rates, and less severe side 
effects than risperidone. In addition, patients treated 
with olanzapine appear to maintain a better response 
than patients treated with risperidone [7]. This 
contrasts with previous findings by Tran et al. (1997) 
which showed differences only in the negative scale, 
in which the group treated with olanzapine had a 
higher score than the group treated with risperidone. 
On the other hand, the positive scale and the total 
score between the two groups were found to be 
comparable [8]. Similarly, Shah et al. (2011) and 
Kumar et al. (2016) reported that although the 
improvement in the negative scale was significantly 
higher in the group treated with olanzapine, there 
were no significant differences for the positive scale 
and the total score of PANSS in both groups [9] [10]. 
Some factors which might influence different 
results in previous studies mentioned above are the 
methods of the patient’s treatment (inpatient or 
outpatient care), the dose of drugs used by the patient 
during the assessment (flexible dose or fixed dose), 
and gender of the patient (male or female). To our 
best knowledge, there is no previous study which 
limits participants only to patients with a specific 
gender. Therefore, this study aimed to measure 
differences in the scores of PANSS on the use of 
olanzapine and risperidone limited to male with 
schizophrenia who were hospitalised with a fixed 
dose. The inpatient method was chosen because this 
method could easily control the physical activity and 
lifestyle of the participants so that the results would 
have a more valid value. The reason for selecting 
male participants was because male schizophrenic 
patients tend to have negative symptoms, a worse 
pre-morbid history, and a greater likelihood of having 
deficit syndromes and worse prognosis than female 
schizophrenic patients [11]. 
 
 
Methods 
 
The research design was a quasi-experiment 
with pre-test and post-test, between the olanzapine 
group and the risperidone group in the period of June-
September 2017. The drop-out criteria used was an 
intention to treat analysis in which if there was a drop -
out subject, the subject would still be included for the 
analysis in the last week with the data used was the 
data recorded in the last week before the subject 
dropped-out [12]. 
The subject used was determined by non -
probability sampling known as the consecutive 
sampling [13]. Subjects who met the criteria were 
required to sign an informed consent after being 
briefed about the study. According to that, this study 
recruited subjects of 68 male patients with 
schizophrenia who were hospitalised in the acute 
phase of treatment at the Mental Hospital Prof. dr. M. 
Ildrem, North Sumatra, Indonesia. These participants 
were divided into two groups based on simple 
randomisation consisting of 34 patients treated with 
olanzapine treatment and 34 patients treated with 
risperidone treatment. If the subject encountered the 
side effects of extrapyramidal symptoms during the 
treatment, the subject would be given anticholinergic 
(i.e. triheksilpenidil) with a dose range of 2-5 mg for 2-
4 times of administration during 1-2 weeks [14] [15]. 
The inclusion criteria were including male patients with 
schizophrenia which corresponded to the Guidelines 
of Diagnostic Classification for Mental Disorders 
IIIprevailed in Indonesia with semi-structured 
interviews mini ICD – 10 [11], in the acute phase of 
treatment (total score of PANSS 80-150) [16], 
between the age of 20 and 45 years, duration of 
illness ≤ 5 years, normal body mass index (BMI = 
18.5-24.99), PANSS excited component (PANSS-EC) 
< 20. The PANSS-EC consisted of 5 items: 
excitement, tension, hostility, uncooperativeness, and 
poor impulse control. It was rated from 1 (not present) 
to 7 (extremely severe) with the score ranged from 5 
to 35 [17]. The exclusion criteria consisted of having 
general medical disorders or other comorbidities, 
history of substance use (except caffeine and 
nicotine), and hypersensitivity or unresponsive to 
olanzapine dan risperidone. 
The administration of olanzapine was carried 
out with an initial dose of 10 mg/day. Then, this dose 
was increased to 15 mg/day on the 7
th day while the 
dose at night was increased to 20 mg/day on the 14
th 
day. The last dose was used for 6 weeks. The initial 
dose of risperidone was 2 mg/day; then this dose was 
increased to 4 mg/day on the 4
th day. Finally, the dose 
was increased to 6 mg/day at the 8
th day. The last 
dose was used in the morning and at night for 6 
weeks. The measurement of PANSS began in the first 
week with the fixed dose. At the end of the research or 
the 6
th week, the total score of PANSS was measured. 
The results measured in each symptom were 
the change in the mean value from the baseline to the 
end-point in the score of PANSS. Before the 
intervention, the baseline was assessed through 
interviews using a questionnaire of PANSS which 
consisted of 30 items with 3 subscales: 7 items were 
the positive symptoms scale (P1-P7), 7 items were 
the negative symptoms scale (N1-N7), and 16 items 
were general psychopathology symptoms scale (G1-
G16). Each item was scored on a 7-point Likert scale 
ranging from 1 to 7. Thus, the range of the positive 
and the negative sub-scales were 7 to 49 while the 
range of the general psychopathology scale was 16 to 
112 [18]. The agreement test was obtained with a 
numerical agreement comparative test (Bland Altman) 
performed by an independent, professional, and 
trained psychiatrist. Furthermore, the scores of 
PANSS of subjects were evaluated on a weekly basis 
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using the same questionnaire with the previous 
questionnaire until the endpoint, the 6
th week. 
The data processing and the statistical 
analysis were performed with the use of IBM SPSS 
statistical software version 22. The baseline 
comparison for the demographic characteristics of the 
subjects was performed using an independent t-test 
(normal distribution) or Mann-Whitney U test (non -
normal distribution), and Chi-Square test. The mean 
score in each group before and after the intervention 
was obtained using paired t-test (normal distribution) 
or Wilcoxon test (non-normal distribution). The mean 
score at the end-point of the 6
th week was obtained 
using an independent t-test or Mann-Whitney U test 
[19]. 
 
 
Results 
 
Table 1 shows the demographic 
characteristics of the olanzapine group (n = 34) and 
the risperidone group (n = 34). Most participants were 
from the primary education level (64.7% for both 
groups) and unmarried status (76.5% for the 
olanzapine group and 85.3% for the risperidone 
group). The mean age of the olanzapine group was 
30.29 years (SD = 6.89), and the mean age of the 
risperidone group was 30.24 years (SD = 6.40).  
Table 1: Demographic characteristics of research subjects 
 
Group of Olanzapine 
Treatment (n = 34) 
Group of Risperidone 
Treatment (n = 34) 
 
Variable 
 
Mean SD Mean SD p 
Age (years) 30.29 6.89 30.24 6.40 0.971* 
Body mass index 22.08 1.45 21.78 1.31 0.386* 
Duration of illness (years) 2.67 1.09 2.50 1.08 0.397** 
Education level N % N %  
Primary 22 64.7 22 64.7 
1.000** 
Middle 12 35.3 12 35.3 
Marriage status 
Married 
 
8 
 
23.5 
 
5 
 
14.7 
 
0.537** 
Unmarried 26 76.5 29 85.3  
*Independent T-test, **Chi-square Test. 
 
The mean duration of illness experienced by 
the subjects was 2.67 years (SD = 1.09) for the 
olanzapine group and 2.50 years (SD = 1.08) for the 
risperidone group. As shown in Table 1, the two 
groups had insignificant differences for all variables 
indicated by the p-value > 0.05. These results indicate 
that the overall results of this study are unbiased. 
Table 2: Baseline of the scores of PANSS (0-week) 
 Group of Olanzapine 
Treatment (n = 34) 
Group of Risperidone 
Treatment (n = 34) 
 
PANSS 
 
Mean SD Mean SD P* 
Positive scale 32.26 2.16 32.62 2.23 0.510 
Negative scale 24.41 2.45 24.35 2.42 0.892 
General 
psychopathology scale 
38.65 3.60 37.91 3.46 0.394 
Total Score 95.26 4.57 94.94 4.33 0.765 
*Independent T-test. 
Table 2 shows the baseline for the scores of 
PANSS at the 0-week. According to the table, there 
was no significant difference between the two groups. 
Table 3: The differences in the PANSS scores before and after 
6 weeks of treatment with olanzapine 
 Before treatment After 6 weeks of 
treatment 
 
PANSS Mean SD Mean SD P*
 
Positive scale 32.62 2.23 12.00 1.02 <0.001 
Negative scale 24.41 2.45 9.03 1.34 <0.001 
General psychopathology scale 37.91 3.46 14.00 1.39 <0.001 
Total Score 94.94 4.33 34.97 2.98 <0.001 
*Paired T-test. 
 
Table 3 and Table 4 show the mean score of 
PANSS in the olanzapine group and the risperidone 
group before and after the treatment. As shown in the 
table, there was a significant change in the positive 
scale, the negative scale, the general 
psychopathology scale, and the total score of PANSS 
of the subjects before and after the treatment in both 
groups. 
Table 4: The differences in the PANSS scores before and after 
6 weeks of treatment with risperidone 
 Before treatment After 6 weeks of 
treatment 
 
PANSS Mean SD Mean SD P*
 
Positive scale 32.26 2.16 16.18 1.40 <0.001 
Negative scale 24.35 2.42 12.38 1.30 <0.001 
General psychopathology scale 38.65 3.60 19.59 1.39 <0.001 
Total Score 95.26 4.57 47.71 2.69 <0.001 
*Paired T-test. 
 
Table 5 shows the differences in the score of 
PANSS after 6 weeks of treatment between the 
olanzapine group and the risperidone group. 
According to the table, the mean of the PANSS score 
in a male with schizophrenia at the end-point of the 6
th 
week for the positive scale in the olanzapine group 
was 12.00 (SD = 1.01) whereas the risperidone group 
showed the mean score of 16.18 (SD = 1.40). The 
mean of the negative scale for the olanzapine group 
was 9.03 (SD = 1.34) while the mean of the negative 
scale for the risperidone group was 12.38 (SD = 1.30). 
The mean of the general psychopathology scale for 
the olanzapine group was 14.1 (SD = 1.39) while the 
mean of the general psychopathology scale for the 
risperidone group was 19.59 (SD = 2.19).  
Table 5: The differences in the PANSS scores after 6 weeks of 
treatment between the olanzapine group and the risperidone 
group 
 Group of 
Olanzapine 
Treatment 
(n = 34) 
 Group of 
Risperidone 
Treatment  
(n = 34) 
  
PANSS Mean SD Mean SD P 
Positive scale 12.00 1.01 16.18 1.40 <0.001 
Negative scale 9.03
 
1.34
 
12.38
 
1.30
 
<0.001 
General psychopathology scale 14.00 1.39 19.59 2.19 <0.001 
Total Score
 
34.97 2.98 47.71 2.69 <0.001 
*Independent T-test. 
 
Thus, the mean of the total score of PANSS 
obtained was 34.97 (SD = 2.98) for the olanzapine 
group and 47.71 (SD = 2.69) for the risperidone 
group. Based on these results, there was a very 
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significant difference between the two groups at the 
end-point of the 6
th week (p-value < 0.001). The 
scores of PANSS obtained from olanzapine group 
showed a higher improvement than that of risperidone 
group. 
 
Figure 1: Mean change from baseline in weekly for positive scale, 
negative scale, general psychopathology scale, and a total score of 
PANSS of male schizophrenic patients treated with olanzapine or 
risperidone (p-value < 0.001) 
 
Figure 1 shows the mean change from 
baseline in weekly scores of PANSS. The decreases 
in the scores of PANSS from baseline to each visit 
were significantly greater in the olanzapine group than 
that in the risperidone group from week 1 through 
week 6. 
 
 
Discussion 
 
This study has provided very clear boundaries 
in recruiting participants as the research subjects. The 
selected participants were male patients aged 20-45 
years. As previously mentioned, the male participants 
were recruited because male patients tend to have 
worse symptoms than female patients. The age 
selection is also because the most frequent onset of 
schizophrenia is the age of 15-30 years whereas the 
peak of the attack in men is between the ages of 10-
25 years. Also, 90% of patients receiving 
schizophrenic treatment are between the ages of 15-
55 years [1]. Patients under the age of 18 were 
excluded from this study as a consideration of their 
long-term safety, including cardiometabolic effects and 
effects on their growth, maturity, and behavioural 
development. In addition, geriatric patients were also 
excluded because these patients experience the 
decreased function of kidney, liver, and heart, and 
increased tendency of postural hypotension [20]. 
As previously explained, the use of 
risperidone and olanzapine in this study was because 
both have been shown to significantly reduce the 
positive symptoms and the negative symptoms of 
schizophrenia [21]. The determination of dose for both 
was based on several studies on olanzapine and 
risperidone in people with schizophrenia. Based on 
monograph products, the daily dose target for people 
with schizophrenia is 10 mg for olanzapine and 6 mg 
for risperidone. However, in clinical practice, the 
average dose of olanzapine and risperidone is 
recommended to be higher than the target dose 
recommended in the monograph [22]. Marder et al. 
(2017) [23] found that olanzapine was effective if 
given in the dose of 10-20 mg/day in the acute phase 
of schizophrenia [23] although a higher dose up to 60 
mg/day was reportedly used for people with 
schizophrenia resistant to treatment. Also, the 
administration of olanzapine at night can improve 
general sedation tolerance in early treatment [24]. On 
the other hand, risperidone has a target dose of 3-6 
mg in a day. Risperidone at a dose of 6 mg is as 
effective as the higher dose, but risperidone at a 
medium dose (4-6 mg/day) suggests a lower risk of 
extrapyramidal symptoms (EPS) than the first 
generation of antipsychotics [21]. Based on the above 
description, it has been determined that the dose of 
olanzapine administered was 20 mg/day and the dose 
of risperidone administered was 6 mg/day because 
this dose would be well tolerated without adverse 
events. 
The calculation results of the scores of 
PANSS in this study showed significant differences in 
the scores of PANSS for the positive scale, the 
negative scale, general psychopathology scale, and 
the total score of PANSS in male schizophrenic 
patients. This is similar to a study conducted by 
Conley et al. (2001) in Los Angeles which compared 
the treatments of olanzapine and risperidone to 134 
patients who were hospitalised. The patients were 
treated with risperidone and olanzapine with flexible 
dose for 8 weeks. In both groups, there was also a 
significant difference in the scores of PANSS for the 
positive scale, the negative scale, general 
psychopathology scale, and the total score of PANSS 
at the end of the 6
th week (p < 0.01) [7]. In contrast, a 
study by Shah et al. (2011) [11] in Nepal found that 
both groups showed significant improvement at the 
end of the 6
th week. More specifically, the negative 
scale was higher in the group treated with olanzapine 
than risperidone while the positive scale and the total 
score of PANSS had improvement, but there was no 
significant difference in the two groups (p = 0.498) [8]. 
This difference was because Shah et al. (2011) used 
participants with the outpatient method, so the 
physical activity and the dose of drugs could not be 
fully controlled while the study by Conley et al. (2001) 
used participants who were hospitalised. 
Nevertheless, Tran et al. (1997) [9] and Kumar et al. 
(2016) [10] who recruited participants who were 
hospitalised also found similar results to the results of 
Shah et al. (2011) [8]. 
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The results of this study were not biased 
because the comparative test results between the 
variables on the demographic characteristics indicated 
that there was no significant difference in terms of 
age, education level, marital status, duration of illness, 
body mass index, positive scale, negative scale, 
general psychopathology scale, and total score of 
PANSS in both groups. 
The limitations of this study were that this 
study did not analyse changes in people’s lifestyle and 
other behaviour patterns, such as smoking. 
In conclusion, the results of this study showed 
that there were significant differences in the scores of 
PANSS including the positive scale, the negative 
scale, general psychopathology scale, and the total 
score of PANSS in male schizophrenic patients 
between the group of olanzapine treatment with the 
fixed dose of 20 mg/day and the group of risperidone 
treatment with the fixed dose of 6 mg/day at the end of 
the 6
th week with the p-value < 0.001. This is in 
accordance with the results obtained by Conley et al. 
(2001) who studied men and women as subjects 
using a flexible dose. Based on these different scores, 
it can also be concluded that olanzapine provides a 
higher improvement in the positive symptoms and the 
negative symptoms than risperidone. 
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